US equities |
NVDA $237.13 ▲+1.36% MU $1,057.57 ▼-1.61% SPCX $163.96 ▲+3.14% MSFT $529.26 ▲+2.27% TSLA $372.61 ▲+0.54% INTC $117.20 ▼-1.78% SNDK $1,727.77 ▲+0.45% AMD $630.38 ▼-0.56%
FinancialContent

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

63.43 -0.76 (-1.18%)
Delayed Quote Updated: 9:47 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
Arrowhead's ARO-AAT Treatment Associated With Improved Fibrosis In Patients With Alpha-1 Liver Disease ↗
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced positive interim 48-week liver biopsy results from the Phase 2 AROAAT2002 study ... 
Via Benzinga
News headline image
Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >